#Germany #Hematology #Düsseldorf #Ozelle #O-Cyte 1

Ozelle Showcases O-Cyte 1 at MEDICA 2026

At the MEDICA 2026 event in Düsseldorf, Germany, Ozelle is set to unveil its revolutionary automated hematology analyzer, the O-Cyte 1. This cutting-edge technology is a game-changer for laboratories, integrating artificial intelligence (AI) into routine hematological practices. With advancements in AI-assisted morphology, the O-Cyte 1 goes beyond simple automated cell classification, addressing the evolving needs of laboratories.

The Future of Hematology

As laboratories incorporate AI-assisted morphology more into their daily routines, it is essential they have tools that support professional review and quality assurance. The O-Cyte 1 combines Complete Blood Count (CBC) testing with high-resolution cell imaging, enabling healthcare professionals to not only obtain numerical results but also review cell images when necessary. This dual capability enhances the verification and reproducibility demanded in modern diagnostics.

The International Council for Standardization in Hematology has endorsed a new digital morphology standardization initiative, illuminating the necessity for quality assurance in digital morphology. With O-Cyte 1, Ozelle emphasizes its commitment to enhancing the reliability and scalability of hematology workflows. The model's AI-assisted cell classification ensures that healthcare providers have access to intelligent, consistent, and reviewable morphology intelligence.

Designed for Efficiency

The O-Cyte 1 is engineered with day-to-day lab operations in mind. Its design supports varying workloads, facilitating seamless integration into diverse laboratory environments. Standing alone, this analyzer can perform up to 60 tests per hour, while linking multiple units in a cascade can achieve an outstanding throughput of 360 tests per hour.

To simplify reagent handling, the O-Cyte 1 features an integrated reagent kit and consumable components, which help minimize routine maintenance. Additionally, it comes equipped with built-in self-checks and replaceable modules, allowing for straightforward fault identification and servicing. Such thoughtful engineering is aimed at easing the operational burden on labs while ensuring their testing needs are met.

Moreover, scalable configurations allow in vitro diagnostic distributors to tailor the O-Cyte 1 to laboratories with varying volumes of testing requirements. This adaptability eases not only the management of reagents but also enhances ongoing technical support and after-sales services for clients.

Additional Offerings at MEDICA

At the MEDICA 2026 exhibition, Ozelle will also introduce additional innovative solutions like the EHBT-75 and EHBT-50. The EHBT-75 combines 7-differential hematology with advanced cell imaging and morphology analysis. In contrast, the EHBT-50 offers an all-in-one platform integrating hematology, immunoassay, and dry biochemistry in a compact design.

Visitors will also have the opportunity to experience Open Dx, Ozelle's AI Workbench, designed for assisted report review and result-sharing for laboratories.

Join Us

Ozelle warmly invites attendees to visit its booth at MEDICA 2026, located in Hall 1, Booth D63, from November 16 to 19. This will be an excellent opportunity to see first-hand the innovative systems and to discuss potential distribution collaborations.

About Ozelle

Founded in Silicon Valley in 2014, Ozelle is at the forefront of developing AI-driven hematology and integrated diagnostic systems tailored for both human and veterinary care. With a commitment to advancing clinical diagnostics, Ozelle merges intelligent analysis with cell imaging, creating solutions ideal for everyday clinical use. Learn more about their pioneering technologies at www.ozellemed.com.